Skip to main content
Premium Trial:

Request an Annual Quote

Paul Doty Dies

Biochemist and nuclear arms control activist Paul Doty has died, reports The New York Times. He was 91. Doty founded the biochemistry and molecular biology department at Harvard University, and recruited James Watson there — Watson considered Doty his mentor, the Times adds. In 1960, Doty and his colleague Julius Marmur reported that DNA come apart and be put back together, a finding that "became a foundation of modern molecular biology."

"This recombination thesis was so counterintuitive that Dr. Marmur and Dr. Doty took bets from doubting fellow scientists, who believed their results were wrong," the Times adds.

In the late 1950s, Doty chaired a group of American scientists who met with Soviet researchers to discuss nuclear arms. "The meetings are believed to have helped lay the scientific foundation for the Anti-Ballistic Missile Treaty between the Soviet Union and the United States signed in 1972," the Times says.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.